Get the Stockscreener App
3.33
2.63%
-0.09
Upstream Bio Inc stock is traded at $3.33, with a volume of 834.50K.
It is down -2.63% in the last 24 hours and down -39.23% over the past month.
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. Verekitug has advanced into three separate world-wide, placebo-controlled, randomized Phase 2 clinical trials, two completed in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, and one ongoing in chronic obstructive pulmonary disease (COPD).
See More
Previous Close:
$3.42
Open:
$3.44
24h Volume:
834.50K
Relative Volume:
0.68
Market Cap:
$182.39M
Revenue:
$3.32M
Net Income/Loss:
$-156.76M
P/E Ratio:
-1.1475
EPS:
-2.9019
Net Cash Flow:
$-140.13M
1W Performance:
-26.81%
1M Performance:
-39.23%
6M Performance:
-66.30%
1Y Performance:
-84.65%
1-Day Range:
$3.285
$3.555
1-Week Range:
$3.29
$4.76
52-Week Range:
$3.285
$33.68
Upstream Bio Inc Stock (UPB) Company Profile
Name
Upstream Bio Inc
Sector
Industry
Phone
781-208-2466
Address
890 WINTER STREET, SUITE 200, WALTHAM
Compare UPB vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UPB
Upstream Bio Inc
|
3.33 | 182.39M | 3.32M | -156.76M | -140.13M | -2.9019 |
VRTX
Vertex Pharmaceuticals Inc
|
508.46 | 128.88B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.99 | 95.01B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
800.59 | 82.42B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
849.61 | 53.43B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
372.06 | 42.09B | 5.76B | 514.49M | 1.10B | 4.4813 |
Upstream Bio Inc Stock (UPB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-12-26 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-03-26 | Initiated | H.C. Wainwright | Buy |
| Mar-27-26 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-18-25 | Initiated | Mizuho | Outperform |
| Nov-18-25 | Initiated | Evercore ISI | Outperform |
| Oct-14-25 | Initiated | Truist | Buy |
| Nov-05-24 | Initiated | JP Morgan | Overweight |
| Nov-05-24 | Initiated | Piper Sandler | Overweight |
| Nov-05-24 | Initiated | TD Cowen | Buy |
| Nov-05-24 | Initiated | William Blair | Outperform |
View All
Upstream Bio Inc Stock (UPB) Latest News
Upstream Bio (UPB) Shares Edge Higher: Stock Gains 3.30% to $4.70Momentum Stock Picks - https://www.dars.gov.et/
Upstream Bio (Nasdaq:UPB)Stock Analysis - simplywall.st
Houghton Adam Disposes of 700 Upstream Bio Shares at $5.49 Each - Kalkine Media
Upstream Bio (UPB) exec offloads shares to cover taxes - Stock Titan
Upstream Bio (UPB) CEO share sale used to cover taxes - Stock Titan
Here's Why We're Watching Upstream Bio's (NASDAQ:UPB) Cash Burn Situation - simplywall.st
Upstream Bio (UPB) Shares Rise on Promising Trial Data, Despite High Price-to-Sales Ratio - GuruFocus
Upstream Bio Presents Results From The Phase 2 VALIANT Trial Of Verekitug For The Treatment Of Severe Asthma - marketscreener.com
A quarterly dose cut asthma flare-ups 56% versus a dummy treatment. Upstream Bio plans Phase 3 trials. - Stock Titan
Upstream Bio Reports Phase 2 VALIANT Trial Results Showing Verekitug Reduced Severe Asthma Exacerbations by 56% with Quarterly Dosing - Quiver Quantitative
Upstream Bio (UPB) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $UPB - MarketBeat
Upstream Bio (NasdaqGS:UPB) Stock Forecast & Analyst Predictions - Simply Wall Street
A new trial for eye-related muscle weakness is planned for 2027. Vor Bio finished enrolling another. - Stock Titan
Upstream Bio to present phase 2 VALIANT trial data on verekitug for severe asthma at ERS 2026 - Traders Union
Upstream Bio Outlines Phase 3 Plans for Verekitug - TipRanks
Upstream Bio on Track to Begin Two Phase 3 Verekitug Trials in Q1 2027 - marketscreener.com
Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP - GlobeNewswire
Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP - Stock Titan
UPB Q2 2026 Earnings: Narrower-than-Expected Loss Delivers 5.03% EPS SurpriseStrong Earnings Momentum - vinanet.vn
Upstream Bio Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Norges Bank Initiates New Position in Upstream Bio Inc (UPB) with 4.2 Million Share Purchase - GuruFocus
UPB Q1 2026 Earnings: Narrower Net Loss Beats Consensus as Pipeline Execution Takes Center StageManagement Tone Analysis - vinanet.vn
UPB Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline in Early-Stage PipelineMargin Compression Risk - vinanet.vn
Walleye Capital LLC Invests $3.45 Million in Upstream Bio, Inc. $UPB - MarketBeat
Upstream Bio (NASDAQ:UPB) Lowered to "Strong Sell" Rating by Wall Street Zen - MarketBeat
Upstream Bio (NASDAQ:UPB) Given New $9.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Q3 EPS Estimates for Upstream Bio Decreased by HC Wainwright - MarketBeat
Marie Sanchirico takes charge of Medical Affairs at Upstream Bio, Inc. to drive physician engagement - Traders Union
Upstream Bio, Inc. (NASDAQ: UPB) Share Price, UPB Stock News, UPB Share Price & Updates - kalkine.ca
Upstream Bio, Inc. (NASDAQ: UPB) Share Price, UPB Stock News, UPB Share Price & Updates - Kalkine
Truist Financial Maintains UpStream Bio(UPB.US) With Buy Rating, Maintains Target Price $25 - Moomoo
H.C. Wainwright Maintains UpStream Bio(UPB.US) With Buy Rating, Maintains Target Price $36 - Moomoo
Upstream Bio (UPB) Slides 2.54% as Biotech Caution Persists: Key Levels to WatchInstitutional Buy Signals - Vinanet
A Quick Look at Today's Ratings for UpStream Bio(UPB.US), With a Forecast Between $19 to $36 - Moomoo
Upstream Bio (UPB) Slides 2.54% as Biotech Caution Persists: Key Levels to WatchStop Hunt - careplusvn.com
Upstream Bio (UPB) Slides 2.54% as Biotech Caution Persists: Key Levels to WatchExhaustion Gap - www.dars.gov.et
Upstream Bio (UPB) Slides 2.54% as Biotech Caution Persists: Key Levels to WatchFundamental Weighted - www.dars.gov.et
Truist Financial Maintains UpStream Bio(UPB.US) With Buy Rating, Cuts Target Price to $25 - Moomoo
Upstream Bio Targets Q1 2027 Start for Phase - Minichart
Upstream Bio (NASDAQ:UPB) Announces Quarterly Earnings Results, Beats Expectations By $0.05 EPS - MarketBeat
Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
UPB: Verekitug demonstrated robust efficacy and safety, advancing to Phase 3 for severe asthma and CRSWNP - TradingView
Upstream Bio posts corporate presentation highlighting verekitug Phase 3 plans in severe asthma, CRSwNP - Bitget
Pstream Bio stock rises 2.6% after Q2 results and pipeline update - Traders Union
Form 8K Upstream Bio Inc For: 11 August By Investing.com - Investing.com Canada
Upstream Bio, Inc. 2Q 2026: Revenue $0.8M, EPS $(0.73) — 10-Q Summary - TradingView
Upstream Bio Q2 net loss narrows slightly on lower R&D costs - TradingView
Upstream Bio reports Q2 2026 net loss $39.7M, cash and short-term investments $261.3M - TradingView
Upstream Bio Posts $39.7 Million Q2 Net Loss as Trials Advance - Quiver Quantitative
Upstream Bio (UPB) deepens R&D spend but ends quarter with $261M cash - Stock Titan
Upstream Bio Inc Stock (UPB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Upstream Bio Inc Stock (UPB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sutherland Everett Rand | Chief Executive Officer |
Sep 16 '26 |
Sale |
5.49 |
2,095 |
11,502 |
68,717 |
| Deykin Aaron | Chief Medical Officer |
Sep 16 '26 |
Sale |
5.49 |
895 |
4,914 |
32,302 |
| Ambrose Allison | General Counsel |
Sep 16 '26 |
Sale |
5.49 |
485 |
2,663 |
15,563 |
| Houghton Adam | Chief Business Officer |
Sep 16 '26 |
Sale |
5.49 |
700 |
3,843 |
22,901 |
| Houghton Adam | Chief Business Officer |
Jun 16 '26 |
Sale |
6.10 |
700 |
4,270 |
23,601 |
| Deykin Aaron | Chief Medical Officer |
Jun 16 '26 |
Sale |
6.10 |
895 |
5,460 |
33,197 |
| Ambrose Allison | General Counsel |
Jun 16 '26 |
Sale |
6.10 |
477 |
2,910 |
16,048 |
| GRAY MICHAEL | CFO and COO |
Jun 16 '26 |
Sale |
6.10 |
853 |
5,203 |
28,795 |
| Sutherland Everett Rand | Chief Executive Officer |
Jun 16 '26 |
Sale |
6.10 |
2,095 |
12,780 |
70,812 |
| Sutherland Everett Rand | Chief Executive Officer |
Mar 16 '26 |
Sale |
9.29 |
2,093 |
19,444 |
72,907 |
3.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):